LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment.
Chen C, He W, Huang J, Wang B, Li H, Cai Q, Su F, Bi J, Liu H, Zhang B, Jiang N, Zhong G, Zhao Y, Dong W, Lin T. · 2018
Read LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. by Chen C, He W, Huang J, Wang B, Li H, Cai Q, Su F, Bi J, Liu H, Zhang B, Jiang N, Zhong G, Zhao Y, Dong W, Lin T. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6148066.txt.
Introduction
Chen and co-authors present a research article in Nature Communications on a long non-coding RNA in bladder cancer. The RNA is called LNMAT1. It runs high in tumors that have spread to lymph nodes. High levels track with lymph node spread and poor outlook. The team asked how it drives that spread.
Raising LNMAT1 sped up the growth of lymph vessels near tumors. Lowering it slowed spread. The RNA switches on a gene called CCL2. CCL2 then draws macrophages into the tumor. Those cells release VEGF-C, which feeds lymph vessel growth. The authors propose LNMAT1 as a treatment target for this cancer.
Catalog record
| CREATOR | Chen C, He W, Huang J, Wang B, Li H, Cai Q, Su F, Bi J, Liu H, Zhang B, Jiang N, Zhong G, Zhao Y, Dong W, Lin T. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment By Changhao Chen, Wang He, Jian Huang, Bo Wang, Hui Li, Qingqing Cai, Feng Su, Junming Bi, Hongwei Liu, Bin Zhang, Ning Jiang, Guangzheng Zhong Published in: Nature Communications DOI: 10.1038/s41467-018-06152-x ABSTRACT Abstract Tumor-associated macrophages (TAMs) are the most abundant inflammatory infiltrates in the tumor microenvironment and contribute to lymph node (LN) metastasis. However, the precise mechanisms of TAMs-induced LN metastasis remain largely unknown. Herein, we identify a long noncoding RNA, termed Lymph Node Metastasis Associated Transcript 1 (LNMAT1), which is upregulated in LN-positive bladder cancer and associated with LN metastasis and prognosis. Through gain and loss of function approaches, we find that LNMAT1 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis. Mechanistically, LNMAT1 epigenetically activates CCL2 expression by recruiting hnRNPL to CCL2 promoter, which leads to increased H3K4 tri-methylation that ensures hnRNPL binding and enhances transcription. Furthermore, LNMAT1-induced upregulation of CCL2 recruits macrophages into the tumor, which promotes lymphatic metastasis via VEGF-C excretion. These findings provide a plausible mechanism for LNMAT1-modulated tumor microenvironment in lymphatic metastasis and suggest that LNMAT1 may represent a potential therapeutic target for clinical intervention in LN-metastatic bladder cancer. INTRODUCTION The tumor microenvironment is comprised of diverse nonmalignant stromal cell types that are associated with tumor progression and metastasis1,2, including tumor-associated macrophages (TAMs), which are the most abundant migratory hematopoietic cell type3,4. Numerous data from clinical and epidemiological studies have shown a strong association between TAMs density and poor prognosis in various types of human cancer5,6, including bladder cancer7,8. Macrophages are heterogeneous cells that respond differently to various microenvironmental signals and thus display distinct roles in each step of cancer progression9. TAMs may promote tumor progression and metastasis by directly affecting the epithelial–mesenchymal transition (EMT)10, extracellular matrix remodeling11 and neo-angiogenesis processes12. Moreover, TAMs accumulation is associated with lymphangiogenesis and upregulation of the lymphogenic factor, vascular endothelial growth factor C (VEGF-C)13,14. However, whether targeting TAMs-mediated lymphangiogenesis could be potential approaches for the therapeutic intervention of bladder cancer lymphatic metastasis remains largely unclear. The chemokine pattern expressed at the tumor site plays a vital role in the orientation and differentiation of macrophage phagocytes, which modulate the suitability of the tumor microenvironment for cancer progression15,16. Chemokine (C-C motif) ligand 2 (CCL2), which is predominantly produced by various cancer types, including bladder cancer17, is particularly important in cancer metastasis18. Tumor-derived CCL2 recruits different subsets of myeloid cells, including TAMs, which contribute to cancer cell proliferation, the inflammatory microenvironment of the tumor, immune response evasion and angiogenesis17,19. Importantly, CCL2 targeting has shown an effective therapeutic impact in preclinical cancer models, in which neutralizing antibodies against CCL2 attenuate 96% of the tumor burden in vivo20. Recently, the CCL2 monoclonal antibody carlumab (CNTO 888) was tested in clinical trials21–23. Therefore, exploring the biological characters and molecular mechanisms underlying sustained CCL2 expression in bladder cancer may provide clinically predictive tools for effective anti-CCL2 treatments. Long noncoding RNAs (lncRNAs), a large class of non-protein-coding transcripts that are over 200 nt in length24, have emerged as key regulators of important biological processes involved in the development and progression of human cancers25,26. LncRNAs, such as HOTAIR, Xist and Drosophila roX2, can serve as molecular scaffolds, recruiting specific regulatory proteins to form unique functional complexes27–29, which suggests that dysregulation of lncRNAs contributes to the development and progression of cancer. Here, we identified an lncRNA LINC01296, termed Lymph Node Metastasis Associated Transcript 1 (LNMAT1), which was markedly upregulated in lymph node (LN)-metastatic bladder cancer and was significantly associated with the clinicopathological characteristics and survival of bladder cancer patients. LNMAT1 overexpression enhanced CCL2 transcription by promoting hnRNPL-mediated H3 lysine 4 trimethylation (H3K4me3) at the CCL2 promoter. Furthermore, LNMAT1-induced CCL2 expression by bladder cancer cells recruited TAMs, which participated in the pro-lymphangiogenic process via VEGF-C excretion and ultimately contributed to lymphangiogenesis and lymphatic metastasis. These findings uncover a mechanism of TAMs-mediated lymphatic metastasis and reveal the oncogenic role of LNMAT1 in bladder cancer progression. RESULTS LNMAT1 correlates with LN-metastasis of bladder cancer To identify critical lncRNAs that contribute to bladder cancer progression, next-generation sequencing (NGS) was performed in five paired high-grade muscle invasive bladder cancer (MIBC) tissues and normal adjacent tissues (NATs) and in another 5 LN-positive and LN-negative bladder cancer tissues. The patient characteristics are shown in Supplementary Table 1. As shown in Fig. 1a, b, 32 and 35 lncRNAs were upregulated and downregulated, respectively, by more than five-fold in the high-grade MIBC tissues compared with the NATs, and 35 and 25 lncRNAs were upregulated and downregulated, respectively, by more than 5-fold in the LN-positive bladder cancer tissues compared with the LN-negative samples. Three lncRNAs, including LNMAT1, CTD-2231H16.1 and BCAR4, were consistently upregulated in both the MIBC and LN-positive bladder cancer tissues (Fig. 1c). Notably, only LNMAT1 was significantly overexpressed in the further validation in a larger cohort of 266 cases of bladder cancer tissues and paired NATs, as determined by quantitative real-time PCR (qRT-PCR) analysis (p < 0.001, Fig. 1d and Supplementary Fig. 1a–c). LNMAT1 is located at human chromosome 14q11.2 (RefSeq accession number: MH666079, Supplementary Fig. 1d). The full-length LNMAT1 in bladder cancer cells is identified by the 5′and 3′ rapid amplification of cDNA ends (RACE) (Supplementary Fig. 1e–f). [Figure: LNMAT1 overexpression is associated with poor prognosis for bladder cancer. a, b Unsupervised hierarchical clustering of the lncRNAs differentially expressed in MIBC tissues and paired normal adjacent tissues NAT (a) and in LN-positive and LN-negative bladder cancer tissues (b). The pseudocolor represents the intensity scale of MIBC tissues vs. NAT or the LN-positive vs. LN-negative bladder cancer tissues, generated by a log2 transformation (fold changes > 5.0, p < 0.01). c Schematic representation of LNMAT1 upregulation in MIBC tissues and LN-positive tissues. d qRT-PCR analysis of LNMAT1 expression in a 266-case cohort of freshly collected human bladder cancer samples and NATs. The nonparametric Mann–Whitney U-test was used. e, f Correlation of LNMAT1 expression in bladder cancer tissues (n = 266) assessed by qRT-PCR with pathological grade (e) and LN status (f). The nonparametric Mann–Whitney U-test was used. g Comparison of LNMAT1 expression in primary human bladder cancer samples and paired metastatic LNs. The nonparametric Mann–Whitney U-test was used. h, i Kaplan–Meier curves for OS (h) and DFS (i) of bladder cancer patients with low vs. high expression of LNMAT1. The median LNMAT1 expression was used as the cutoff value. j‚ k Representative images (j) and percentages (k) of the ISH of LNMAT1 expression (blue) in the paraffin-embedded NAT and tumor sections of bladder cancer with or without LN metastasis (n = 266). Samples were counterstained with nuclear fast red. The scramble probe was used as a negative control. Statistical significance was assessed by χ2 test. Scale bars: 50 μm. The error bars represent standard deviations of three independent experiments. *p < 0.05 and **p < 0.01] Furthermore, statistical analysis revealed that LNMAT1 expression was strongly correlated with pathological grade (Fig. 1e) and LN metastasis status (Fig. 1f) in a large cohort of bladder cancer patients (n = 266; Supplementary Table 2). The qRT-PCR analysis showed that LNMAT1 overexpression was apparent in metastatic tumor cells in the LNs compared with the paired primary tumors, suggesting that LNMAT1 might be a key component of metastatic cells (Fig. 1g).